Log in
FREE 15-Day Trial
Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. GEN2

Genesis Research & Development Corporation Limited (ASX: GEN2) - Share Price and Research

DELISTED

Intelligent Investor free trial for buy hold sell stock recommendations

GEN2 General Information +

ASX Code GEN2
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) n/a
GEN2 Share Price N/A
Day High N/A
Day Low N/A
Last Close N/A
GEN2 Share Price Movement N/A
+Security prices are delayed by at least 20 minutes and are indicative only.
Trial Banner Trial Banner Trial Banner
Upsell Banner

GEN2 Related Research

Genesis Research & Development Corporation Limited (GEN2) Upcoming Dividends & Yields

There are no dividends for Genesis Research & Development Corporation Limited (GEN2). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Genesis Research & Development Corporation Limited (GEN2) Recent ASX Announcements

There are no announcements from Genesis Research & Development Corporation Limited (GEN2). Please use our ASX Announcements tool to search for announcements across all ASX-listed securities.

GEN2 Directors

Name Position Start Date
Mr Stephen Hall Company Secretary, Chief Executive Officer 17 Dec 2004
Mr Gude Buer Executive Director 19 Dec 2012
Mr Joachim(Aki) Herbert von Roy Non-Executive Chairman 17 Jun 2005
Dr Steven Gillis Non-Executive Director 2 Dec 1993
Dr Andrew (Andy) John Hubert Gearing Non-Executive Director 26 Jan 2006
Mr Daniel Mahnert-Lueg Non-Executive Director 14 Mar 2011
Mr Christopher Manie Non-Executive Director 8 Feb 2013
Ms Sharon Kwan Non-Executive Director 8 Aug 2013
Mr Frankie Chen Non-Executive Director 8 Aug 2013
Mr Phi San Lam Non-Executive Director 8 Aug 2013

Genesis Research & Development Corporation Limited (GEN2) Changes in Directors' Interest & Trades

There are no directors' trades from Genesis Research & Development Corporation Limited (GEN2). Please use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

GEN2 Management

Name Position
Gregory (Greg) Murison Chief Scientific Officer
Diana Gash Head of Clinical and Regulatory Affairs
Anand Kumble Head of Product Development

GEN2 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in -- (GEN2). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
7,437,941 (16.35%) UBNZ Funds Management Limited
4,427,435 (9.70%) Bagnall, Nicholas Stuart
4,370,000 (9.60%) Accident Compensation Corporation

FAQs about Genesis Research & Development Corporation Limited (GEN2)

Relative to the previous close share price of , Genesis Research & Development Corporation Limited's (GEN2) current share price of constitutes a movement of or . Genesis Research & Development Corporation Limited's (GEN2) share price movement is when compared to 7 days ago and is n/a below GEN2's 52-week high of n/a.

Genesis Research & Development Corporation Limited (GEN2) has a current dividend yield of n/a this year. Last year's dividend yield was n/a. The dividend yield for GEN2 is a ratio that tells you the percentage of Genesis Research & Development Corporation Limited's (GEN2) share price that it pays out in dividends each year.

Genesis Research & Development Corporation Limited (GEN2) will release its next Annual Report on n/a. Genesis Research & Development Corporation Limited's (GEN2) last annual report was released on n/a.

Genesis Research & Development Corporation Limited (GEN2) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.